Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03135249
Recruitment Status : Completed
First Posted : May 1, 2017
Last Update Posted : December 22, 2020
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Olaf Stuve, University of Texas Southwestern Medical Center

Brief Summary:
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple sclerosis (RRMS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis (MS) Drug: Alemtuzumab Phase 4

Detailed Description:

To determine if treatment with alemtuzumab after natalizumab reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy. The target population for this study are RRMS patients nearing the end of their natalizumab treatment regimen.Participants will be recruited from four different sites. Patients who meet all inclusion/exclusion criteria will be eligible for enrollment in the study.

Alemtuzumab (Lemtrada®) will be administered at a dose of 12 mg/d by intravenous (i.v.) infusion every day for five consecutive days within 14 days of the last dose of natalizumab. After 12 months, patients will be treated with a second course of alemtuzumab 12 mg/d by intravenous (i.v.) infusion every day for three consecutive days, and participants will be followed open-label for another 12 months per standard of care. Outside the scope of this study, the intention is to follow all study participants in participating centers long-term, and to record disease activity and treatment response.

Natalizumab treatment sequesters leukocytes out of the central nervous system (CNS) into the peripheral blood. Immediate sequential alemtuzumab therapy will deplete these cells more completely than alemtuzumab monotherapy, and prevent reactivation of disease activity previously treated with natalizumab. Thus, investigators hypothesize that sequential natalizumab - alemtuzumab therapy will prevent disease activation after cessation of natalizumab, and will provide sustained disease remission in many patients.

Clinical follow up by the treating physician will occur at months 0, 3, 6, 9, 12, 18 and 24 or immediately following clinical exacerbations months. During clinical visits, comprehensive medical history data will be obtained by the treating physician. Clinical visits due to suspected exacerbations associated with CNS (central nervous system) demyelination, and associated diagnostic studies and treatments, will be covered under the medical standard of care by third party payers. A recommendation to reevaluate the patient within 3 months following the clinical event to assess for extent of recovery will be made.

Standardized MRI studies of the brain will be performed at 0, 6, 12 and 24 months. Clinical imaging studies of the brain will be performed during or immediately following the onset of a clinical exacerbation will be performed at the discretion of the site PI with scan costs covered under the medical standard of care. An end of study clinical MRI of the brain with and without contrast will be recommended to study participants at week 96 as medical standard of care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: To determine if treatment with alemtuzumab after natalizumab maintains or reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)
Actual Study Start Date : January 1, 2018
Actual Primary Completion Date : November 4, 2020
Actual Study Completion Date : November 4, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Alemtuzumab treatment.

Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:

Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.

Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution.

Drug: Alemtuzumab
Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
Other Name: Lemtrada




Primary Outcome Measures :
  1. Annualized relapse rate (ARR) from the time of cessation of natalizumab treatment. [ Time Frame: 2 years ]
    To determine if treatment with alemtuzumab after natalizumab maintains or reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy.


Secondary Outcome Measures :
  1. Relapse-free period [ Time Frame: 12 months ]
    To determine the freedom of relapse

  2. Magnetic resonance imaging outcomes [ Time Frame: 24 months ]
    To determine the number of new/enlarging T2 lesions, and the number of gadolinium (Gd)-enhancing lesions


Other Outcome Measures:
  1. Neurological disability outcome [ Time Frame: 24 months ]
    The Expanded Disability Status Scale (EDSS) will be utilized to measure the accumulation of neurological disability

  2. Anterior visual pathway outcome [ Time Frame: 24 months ]
    To determine the effect on the retinal nerve fiber layer (RNFL), optic coherence tomography (OCT) will be performed.

  3. Quality of Life outcome [ Time Frame: 24 months ]
    Quality of life (QoL) will be measures by a pre-defined, self-administered testing battery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 18 and 60 years, inclusive.
  2. Diagnosis of relapsing forms of MS using revised McDonald Criteria1.
  3. Expanded Disability Status Scale (EDSS) 0 - 5.5 (note: functional system changes in cerebral (or mental) functions and in bowel and bladder functions not used in determining EDSS for protocol eligibility).
  4. Has had a minimum of 12 monthly doses of continuous natalizumab therapy (300 mg/d).
  5. Understands English, and gives informed consent.

Exclusion Criteria:

  1. Natalizumab failure based on clinician's discretion.
  2. Any prior exposure to alemtuzumab.
  3. Progressive MS.
  4. A diagnosis of Progressive multifocal leukoencephalopathy (PML).
  5. Known hypersensitivity to alemtuzumab.
  6. Initiation of new immunosuppressant treatment after the subject becomes protocol-eligible (except for corticosteroids) or enrollment in a concurrent trial with immuno-active pharmacotherapies.
  7. Uncontrolled diabetes mellitus defined as HbA1c > 8% and/or requiring intensive management.
  8. History of cytopenia consistent with the diagnosis of myelodysplastic syndrome.
  9. Clinically significant autoimmune disease other than MS that may affect the CNS, including neuromyelitis optica (NMO), systemic lupus erythematosus (SLE), or Behcet disease.
  10. Active hepatitis B or C infection or evidence of cirrhosis.
  11. HIV positivity.
  12. Uncontrolled viral, fungal, or bacterial infection.
  13. Positive pregnancy test or inability or unwillingness to use effective means of birth control. Effective birth control is defined as:

    1. Refraining from all acts of vaginal intercourse (abstinence),
    2. Consistent use of birth control pills,
    3. Tubal sterilization or male partner who has undergone vasectomy
    4. Placement of intrauterine device
    5. Use, with every act of intercourse, of a diaphragm with contraceptive jelly and/or condoms with contraceptive foam.
  14. Presence of metallic objects implanted in the body that would preclude the ability of the subject to safely have MRI exams.
  15. Psychiatric illness, mental deficiency, or cognitive dysfunction making compliance with treatment or informed consent impossible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03135249


Locations
Layout table for location information
United States, Texas
VA North Texas Health Care System
Dallas, Texas, United States, 75216
UT Southwestern Medical center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Genzyme, a Sanofi Company
Investigators
Layout table for investigator information
Principal Investigator: Olaf Stuve, M.D., Ph.D. UT Southwestern Medical Center
Publications:

Layout table for additonal information
Responsible Party: Olaf Stuve, PROFESSOR, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT03135249    
Other Study ID Numbers: STU 112016-060
First Posted: May 1, 2017    Key Record Dates
Last Update Posted: December 22, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Alemtuzumab
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents